Aberrant cytokeratin subset immunoreactivity in sarcomas using a large panel of cytokeratin subset antibodies

被引:6
作者
Alobeid, B [1 ]
Brooks, JJ [1 ]
Zhang, PJ [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA
来源
APPLIED IMMUNOHISTOCHEMISTRY | 1998年 / 6卷 / 03期
关键词
cytokeratin; aberrant reaction; sarcomas; immunohistochemistry;
D O I
10.1097/00022744-199809000-00009
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
A large panel of cytokeratin (CK) subset antibodies was tested in a variety of sarcomas to evaluate their specificity in the differential diagnosis of sarcoma versus spindle cell carcinoma. Seventy-five different sarcomas were immunostained with AE1/3, CAM5.2, 34BE12, and antibodies against CK5/6, CK7, CK8, CK13, CK14, CK19, and CK20 on paraffin sections. Two other epithelial markers, epithelial membrane antigen and desmosomal glycoprotein, were also tested. Fifteen of 75 (20%) sarcomas showed immunoreactivity with one or more antibodies tested in the panel. Forty-seven percent of CK-positive sarcomas showed immunoreactivity with more than one antibody. Except for CK8, CK subset immunoreactivity was focal and weak in most instances. Among the sarcomas tested, gastroin testinal stromal tumor most frequently showed CK reactivity (50%), with CK8 being the most frequent (38%). Compared with the immunoreactivity with CK8 or CAM5.2 (13% and 9%, respectively), the new subset antibodies (CK5/6, CK7, CK13, CK14, and CK20) showed a low incidence of focal and weak aberrant expression (2%-5%). These new CK subset antibodies may be useful in the differential diagnosis of spindle cell carcinoma versus sarcoma, given the low frequency of aberrant reactivity in nonepithelial tumors.
引用
收藏
页码:154 / 157
页数:4
相关论文
共 12 条
[1]  
CHENEY RT, 1997, LAB INVEST
[2]  
Hazelbag HM, 1996, APPL IMMUNOHISTO M M, V4, P176
[3]  
LITZKY LA, 1992, MODERN PATHOL, V5, P30
[4]  
MIETTINEN M, 1991, AM J PATHOL, V138, P505
[5]  
MIETTINEN M, 1993, PATHOL ANNU, V28, P113
[6]  
MIETTINEN M, 1995, MODERN PATHOL, V8, P384
[7]  
MIETTINEN M, 1988, ARCH PATHOL LAB MED, V112, P637
[8]  
PALMAN C, 1990, MODERN PATHOL, V3, pA77
[9]   EXPRESSION OF EPITHELIAL MARKERS IN MALIGNANT FIBROUS HISTIOCYTOMA OF THE MUSCULOSKELETAL SYSTEM - AN IMMUNOHISTOCHEMICAL AND ELECTRON-MICROSCOPIC STUDY [J].
ROSENBERG, AE ;
OCONNELL, JX ;
DICKERSIN, GR ;
BHAN, AK .
HUMAN PATHOLOGY, 1993, 24 (03) :284-293
[10]   SPINDLE-CELL CARCINOMA OF THE ORAL CAVITY AND LARYNX - IMMUNOHISTOCHEMICAL ASPECTS [J].
SLOOTWEG, PJ ;
ROHOLL, PJM ;
MULLER, H ;
LUBSEN, H .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 1989, 17 (05) :234-236